In our study, we aimed to explore the relationship between blood biomarkers in melanoma, such as lactate dehydrogenase (LDH), C-reactive protein (CRP) and S-100B, with imaging-based total tumor burden in metastatic melanoma patients treated with immune checkpoint inhibition. The gene discussed is CRP; the disease is melanoma.